Biomarker for immune checkpoint blockade therapy in nsclc
Patent Information
- Application Number
- PCT/CN2023/094890
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-17
- Publication Date
- 2024-11-21
Smart Images

Figure CN2023094890_21112024_PF_FP_ABST
Abstract
Description
BIOMARKER FOR IMMUNE CHECKPOINT BLOCKADE THERAPY IN NSCLCTECHNICAL FIELD
[0001] The present application relates to the technical field of cancer treatment, and in particular, to a biomarker for immune checkpoint blockade (ICB) therapy in non-small cell lung cancer (NSCLC) , more specifically, a biomarker for assessing response of NSCLC subject to taxifolin-treatment in ICB therapy.BACKGROUND
[0002] Lung cancer (LC) ranks 2nd in diagnosed cancer incidences in 2020, just behind breast cancer, constituting 11.4%of the 19.3 million new cancer cases. As a leading cause of cancer death, LC contributes to 18%of 10 million cancer fatalities in 2020. Men have approximately 2-fold higher rates of LC incidence and mortality than women (Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians. 2021; 71 (3) : 209-49) . The disease is composed of 2 histological types: small-cell lung cancer (SCLC, 15%) and non-small-cell lung cancer (NSCLC, 85%) . The NSCLC contains 3 subtypes: lung adenocarcinoma (LUAD) , lung squamous cell carcinoma (LUSC) , and large cell carcinoma, each constituting 50%, 30%, and 10%of NSCLC cases respectively. LUAD and LUSC are the main types of NSCLC and the major contributors to LC mortalities. While LUAD and LUSC are driven by activation of the pathways regulating proliferation, cell cycle progression, cell survival, and oxidative stress response, their respective alterations relevant to the pathways are different. Scientists are constantly searching for various methods that can effectively inhibit the progression of different types of lung cancer and treat lung cancer.
[0003] Since the 2015 FDA approval of nivolumab (anti-PD-1) as a second-line therapy for advanced NSCLC progressed on previous platinum-based chemotherapy, ICB therapy has gained its recognition as a first-line treatment for NSCLC in advanced and early stages. However, only a fraction of NSCLC patients responded to ICB therapy and many of them experienced disease progression. Additionally, ICB treatment can instigate severe immune-related adverse events (irAEs) , which may be lethal. PD-L1 expression is the most reliable biomarker currently used in NSCLC but PD-L1 performed poorly in selecting patients for ICB therapy (Catalano M, Shabani S, Venturini J, Ottanelli C, Voltolini L, Roviello G, Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors. Cancers (Basel) . 2022; 14 (24) ) . To improve management of patients treated with ICB, development of better biomarkers to stratify patients who will benefit from ICB treatment is a priority.
[0004] Despite the use of targeted therapies and recently emerged ICB treatments, LC remains the leading cause of cancer death. For patients with NSCLC that do not benefit from targeted treatments (which include almost all LUSCs) , ICB treatment is becoming the first-line or standard of care. However, only a fraction of patients with NSCLC responds and a large proportion showed disease progression even with treatments; the situation thus calls for more robust biomarkers in selecting the right patients for ICB therapy, and for exploration of more effective ICB options. For both tasks, more novel targets and new ICB therapeutic regimens are needed.
[0005] Taxifolin (dihydroquercetin) , a flavonoid with established antioxidant and anti-inflammatory properties, might be beneficial in NSCLC therapy. Taxifolin displayed anticancer activities both in vitro and in vivo (xenografts) towards colorectal cancer, liver cancer, skin cancer, osteosarcoma, gastric cancer, glioma, prostate cancer, cervical cancer, breast cancer, and lung cancer. The anti-cancer impact of taxifolin was attributable to activate the Nrf-mediated anti-ROS (reactive oxygen species) cytoprotective pathway, Wnt / β-catenin signaling, p53, etc. Given somatic mutations in TP53 occurring in LUSC and LUAD, it will be appealing to thoroughly investigate taxifolin-derived anti-oncogenic activities towards LUAD and LUSC. This concept is particularly attractive, considering taxifolin’s role as a nutritional supplement and its health-promoting effects.
[0006] Based on the above, in combination with taxifolin treatment, calling for more robust biomarkers in selecting the right patients for ICB therapy, and for exploration of more effective ICB options may be an urgent task for current LC treatment.SUMMARY
[0007] One object of the disclosure is to provide one or more novel biomarkers in predicting or assessing LC, more particularly NSCLC, response to ICB therapy.
[0008] Another object of the disclosure is to investigate the mechanisms underlying taxifolin-derived inhibition of LC, which opens the possibility of including taxifolin in the current regimen of ICB therapy in LC, more particularly NSCLC.
[0009] The above objects are achieved by the following technical solutions.
[0010] In an embodiment of the disclosure, there is provided a biomarker for assessing LC response to ICB therapy, where the biomarker is selected from at least one of ITGAL, ITGAX, TMEM119, STRA6, MINK1, NBEAL2, GBP4, GFRA4, SLIT3, ARHGDIB, ASCL2, ACP5, PRDX6, MAGOHB, NUCKS1, DCAF13, and TXN, or any combination thereof.
[0011] Further, the seven genes ITGAL, ITGAX, TMEM119, STRA6, MINK1, NBEAL2, and GBP4 may be combined into a 7-gene panel TxflSig1.
[0012] Further, the twelve genes ITGAL, ITGAX, TMEM119, STRA6, MINK1, NBEAL2, GBP4, GFRA4, SLIT3, ARHGDIB, ASCL2 and ACP5 may be combined into a 12-gene panel TxflSig.
[0013] In an embodiment of the disclosure, the biomarker is a combination of ITGAL, ITGAX, and TMEM119, which is abbreviated to “IIT” ; a combination of ITGAL, ITGAX, TMEM119, STRA6, MINK1, NBEAL2, and GBP4; or a combination of ITGAL, ITGAX, TMEM119, STRA6, MINK1, NBEAL2, GBP4, GFRA4, SLIT3, ARHGDIB, ASCL2, and ACP5; or a combination of PRDX6, MAGOHB, NUCKS1, DCAF13, and TXN.
[0014] In an embodiment of the disclosure, the biomarker is ITGAL, ITGAX, or TMEM119.
[0015] Further, the LC may be SCLC or NSCLC, where, the NSCLC is one of LUAD, LUSC, and large cell carcinoma.
[0016] Further, the biomarkers ITGAL, ITGAX, TMEM119, STRA6, MINK1, NBEAL2, and GBP4 each are down-regulated in a LC subject under taxifolin-treatment.
[0017] Further, the biomarkers PRDX6, MAGOHB, NUCKS1, DCAF13, and TXN each are up-regulated in a LC subject under taxifolin-treatment.
[0018] Further, in the taxifolin-treatment, the taxifolin is administered to the LC subject at a therapeutically effective amount of about 5-100 mg / kg body weight.
[0019] In an embodiment of the disclosure, the taxifolin is administered to the LC subject at a therapeutically effective amount of about 10-90 mg / kg body weight, about 20-80 mg / kg body weight, about 30-60 mg / kg body weight, or about 40-70 mg / kg body weight.
[0020] In an embodiment of the disclosure, the taxifolin may be administered to the LC subject at a therapeutically effective amount of about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 mg / kg body weight, preferably, 50 mg / kg body weight.
[0021] In an embodiment of the disclosure, there is provided a kit for assessing a response of a LC subject to taxifolin-treatment, including a detecting agent for detecting expression of the above biomarker in the LC subject, and an instruction for use.
[0022] In an embodiment of the disclosure, there is provided a method for assessing a response of a LC subject to taxifolin-treatment, including: determining an expression level of at least one of the above biomarkers in a biological sample obtained from the LC subject after taxifolin-treatment, and comparing the expression level with an expression level of the at least one of the above biomarkers in a biological sample obtained from the LC subject before taxifolin-treatment. Optionally, the biological sample may be tumor issue.
[0023] Further, the method further includes: determining the taxifolin-treatment is effective when the LC subject has a positive response to the taxifolin-treatment.
[0024] Further, the positive response to the taxifolin-treatment is indicative of high drug sensitivity and good prognosis of LC on the taxifolin, such as no recurrence of lung cancer, reduced tumor growth of lung cancer, reduced tumor volume of lung cancer, alleviated symptoms of lung cancer, and high overall survival probability.
[0025] Further, the method further includes: determining the taxifolin-treatment is effective when one or more of biomarkers ITGAL, ITGAX, TMEM119, STRA6, MINK1, NBEAL2, and GBP4 is down-regulated; or one or more of biomarkers PRDX6, MAGOHB, NUCKS1, DCAF13, and TXN is up-regulated.
[0026] In an embodiment of the disclosure, there is provided a method for preventing or treating lung cancer, including performing an ICB therapy on a LC subject alone, optionally in combination with taxifolin treatment.
[0027] In an embodiment of the disclosure, there is provided a method for preventing or treating lung cancer, including administering to a subject in need a therapeutically effective amount of taxifolin, a derivative thereof, or pharmaceutical salts thereof, where the subject has a positive response to taxifolin-treatment.
[0028] Further, the taxifolin, a derivative thereof, or pharmaceutical salts thereof may be formulated into a composition in a form of a tablet, a pill, a powder, a granule, a solution, a suspension, a capsule, an oral liquid, an injection, or infusion.
[0029] In an embodiment of the disclosure, the composition may be administered alone, or in combination with an immune checkpoint inhibitor, such as PD-1 and PD-L1 inhibitors.
[0030] In an embodiment of the disclosure, there is also provided a method for assessing taxifolin sensitivity of a subject, including using the above kit to determine the expression of the biomarker in the subject, where the biomarker is one or more of selected from the above biomarkers; and the subject is one suffering from a LC or at a risk of suffering from the LC, preferably, the LC is NSCLC.
[0031] In an embodiment of the disclosure, there is also provided a method for preventing, alleviating or treating LC, in particular, NSCLC in a subject, including administering taxifolin or derivative thereof, or a pharmaceutical acceptable salt thereof to a subject that is underwent an ICB therapy, and determining a level of a biomarker in tumor cell from the subject, where the biomarker is selected from at least one of ITGAL, ITGAX, TMEM119, STRA6, MINK1, NBEAL2, GBP4, GFRA4, SLIT3, ARHGDIB, ASCL2, ACP5, PRDX6, MAGOHB, NUCKS1, DCAF13, and TXN, or any combination thereof.
[0032] In an embodiment of the disclosure, there is provided a use of taxifolin and immune checkpoint inhibitor for preventing, alleviating or treating a subject with LC, in particular NSCLC, including administering taxifolin or derivative thereof, or a pharmaceutical acceptable salt thereof to a subject that is underwent an ICB therapy, and determining a level of a biomarker in tumor cell from the subject, where the biomarker is selected from at least one of ITGAL, ITGAX, TMEM119, STRA6, MINK1, NBEAL2, GBP4, GFRA4, SLIT3, ARHGDIB, ASCL2, ACP5, PRDX6, MAGOHB, NUCKS1, DCAF13, and TXN, or any combination thereof.
[0033] In an embodiment of the disclosure, the immune checkpoint inhibitor for the above ICB therapy may be any agent that functions on conventional immune checkpoints in tumor cells, for example, the immune checkpoints may be one or more of Programmed Cell Death Protein 1 (PD1) , Cytotoxic T-Lymphocyte Associated Antigen 4 (CTLA4) , Lemur Tyrosine Kinase 3 (LMTK3) , T Cell Immunoglobulin Mucin Receptor 3 (TIM3) , Indoleamine-2, 3-Dioxygenase (IDO) , and others.
[0034] According to the disclosure, both 12-gene (TxflSig) and 7-gene (TxflSig1) panel are useful for predicting response to ICB therapy more effectively in NSCLC compared to numerous well-established ICB biomarkers including PD-L1. In both panels, the mouse counterparts of ITGAL, ITGAX, and TMEM119 genes are down-regulated by taxifolin, which are strongly associated with immune suppression in LC, evident by their robust correlations with the major immunosuppressive cell types (MDSC, Treg, and macrophage) and multiple immune checkpoints in NSCLC and across multiple human cancer types. ITGAL, ITGAX, and IIT (ITGAL-ITGAX-TMEM119) effectively predict LC such as NSCLC’s response to ICB therapy; IIT stratified the mortality risk of NSCLC. In addition, taxifolin reduces NSCLC partially via sensitizing immune response. TxflSig, TxflSig1, IIT, ITGAL, and ITGAX are novel ICB biomarkers for LC, particularly for NSCLC. The association of ITGAL, ITGAX, and TMEM119 with NSCLC immune evasion is novel; as well, TMEM119 is a novel LC gene. This research may significantly improve the management of patients with NSCLC.BRIEF DESCRIPTION OF DRAWINGS
[0035] To describe the technical solutions in embodiments of the present disclosure or in the relevant art more clearly, the following briefly introduces the accompanying drawings for describing the embodiments or the relevant art. Apparently, the accompanying drawings in the following description illustrate merely some but not all of the embodiments of the present disclosure and persons of ordinary skill in the art may still derive other drawings from these accompanying drawings without creative effort.
[0036] FIG. 1. Taxifolin-derived inhibition of lewis lung carcinoma (LL2) lung tumor growth. A, B: LL2 tumors were produced in C57BL / 6 mice, treated with either DMSO or taxifolin (Tax) , and harvested at day 28 post tumor implantation. Images and tumor weights of individual tumors are shown. The marked tumor portion of DMSO tumor #5 was from a peritoneal metastasis mass (A) . Quantification was provided with statistical analysis performed using 2-tailed Student’s t-test, *p < 0.05 (B) . C: RNA-seq analysis of LL2 tumors treated with DMSO (n = 3) or taxifolin (n = 3) . Heatmap is generated for differentially expressed genes (DEGs) derived from the indicated treatments. D: Summary of GO GSEA analysis using the gene expression profile of LL2 tumors treated with DMSO or taxifolin. Enrichment analysis was performed using the R package of ClusterProfiler (Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16 (5) : 284-7) . E: A typical GSEA analysis using the Hallmark gene set within the MSigDB gene set collection; the analysis was performed using Galaxy. NES: normalized enrichment score. F, G: GO enrichment analyses were performed using up-regulated and down-regulated DEGs in LL2 tumors treated with taxifolin. Note: in panel F, Padj value of each dot is equal to or smaller than 1.2*10-5; in panel G, each Padj value of each dot is equal to or smaller than 1.6*10-4.
[0037] FIG. 2. Taxifolin DEGs predict NSCLC response to ICB therapy. A. Association of the indicated DEGs with T cell dysfunction value (top panel) and inferior overall survival in the indicated cancer populations treated with the indicated ICB (bottom panel) . Ipi: Ipilumumab anti-CTLA4; Prog: progressed; PD1. Ipi_Prog and PD1. Ipi_Naive: treatment of melanoma by anti-PD1 on tumor progressed or naive on Ipi. *: the mouse homologous genes were downregulated in LL2 tumors treated with taxifolin; these genes formed a multigene panel TxflSig1, while all 12 genes were formulated to TxflSig. B. Prediction of response to ICB therapies in NSCLC and other indicated cancer cohorts by TxflSig and TxflSig1 along with a set of published ICB biomarkers. The analysis was performed using the TIDE platform with cohort details listed there (Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nature medicine. 2018; 24 (10) : 1550-8) . C. Prediction of response to ICB therapies in two NSCLC datasets using the TIDE platform with ITGAL, ITGAX, IIT (ITGAL+ITGAX+TMEM119) , and other well-studied ICB biomarkers. D-H. Stratification of overall survival (OS) in the indicated cancer cohorts treated with the indicated ICB therapies by TxflSig, TxflSig1, ITGAL, ITGAX, and IIT. Top panel: Kaplan-Meier survival curves for the indicated biomarkers; bottom panel: summary of mortality risk stratified by our biomarkers along with a set of well-studied ICB biomarkers.
[0038] FIG. 3. Robust correlation of ITGAL, ITGAX, and TMEM119 with multiple immune checkpoints. A. Spearman correlations (Corr) of ITGAL and ITGAX with the immune checkpoints, as indicated in the Y axis, in LUAD (n = 510) and LUSC (n = 501) were determined using cBioPortal with the tools provided. B., C. Systemic analyses of spearman correlation between ITGAL, ITGAX, or TMEM119 and the indicated immune checkpoints in LUAD and LUSC were performed with the TISIDB platform (Ru B, Wong CN, Tong Y, Zhong JY, Zhong SSW, Wu WC, et al. TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019; 35 (20) : 4200-2) , except PVRIG (poliovirus-related immunoglobulin domain-containing) , an immune checkpoint, which was determined using cBioPortal. Those immune checkpoints were presented if Spearman rho is ≥ 0.5 for one of ITGAL, ITGAX, and TMEM119.
[0039] FIG. 4. Association of taxifolin-affected DEGs with immune cells infiltrated in LUAD and LUSC. A. Spearman correlations of ITGAL and ITGAX with the content of MDSC and Treg in LUAD and LUSC were obtained using TISIDB. B. C. Systemic analyses of spearman correlations of ITGAL, ITGAX, and TMEM119 with a set of immune cells within the TISIDB platform. Individual immune cell types are included if the correlation for one of the three factors is ≥ 0.5. D., E. Spearman correlations of the indicated genes with Treg, MDSC, and macrophages in LUAD and LUSC.
[0040] FIG. 5. Expression of ITGAL, ITGAX, and TMEM119 in LUAD and LUSC. Analyses were performed using The Cancer Genome Atlas (TCGA) dataset organized by UALCAN (Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017; 19 (8) : 649-58) . *, **, ***, and ****: p < 0.05, 0.01, 0.001, and 0.0001 respectively in comparison to normal tissues; $, $$, and $$$: p < 0.05, 0.01, and 0.001 respectively in comparison to stage1 tumor (D-F) , N0 tumor (G) , or tumors without TP53 mutation (N-P) ; #: p < 0.05 compared to stage2 tumors (E, F) .
[0041] FIG. 6. ITGAL, ITGAX, and TMEM119 protein expression in LUAD and LUSC. Immunohistochemistry (IHC) staining of LUAD and LUSC tissue microarray for ITGAL, ITGAX, and TEME119 protein was downloaded from the Human Protein Atlas. The marked regions were enlarged 2.2-fold. T: tumor cells; TN: tumor necrosis; L: immune cells; and S: stroma.
[0042] FIG. 7. Prediction of OS by IIT. A. The risk score of IIT (ITGAL+ITGAX+TMEM119) was calculated for individual tumors within the TCGA PanCancer Atlas LUAD dataset, followed by estimation of cutoff point by Maximally Selected Rank Statistics with the R Maxstat package, construction of Kaplan Meier curves, and log-rank test analysis. B. Univariate (UV) and multivariate (MV) Cox analysis of LUAD mortality risk using IIT and the indicated clinical features. Sex: men compared to women; Mstage: M1 versus M0; Nstage: 1 (N1) and 2 (N ≥ 2) compared to N0; Tstage: T1, T2, and T3 (T3+T4) compared to T0. C. Stratification of mortality risk by IIT together with the above clinical features (IIT+Clinicalfeature) . D., E. Discrimination of OS by IIT+Clinicalfeature with ROC-AUC (receiver operating characteristic-area under the curve) and precision recall (PR) -AUC curves for LUAD. F. Cutoff points of IIT+Clinicalfeature risk score in stratification of LUAD were estimated by the maxstat, empirical, normal, and kernel method, followed by the construction of individual survival curves; the individual cutoff points and their associated specificity and sensitivity are presented.
[0043] FIG. 8. Taxifolin-mediated enrichment of pathway in LL2 tumors. A. GSEA analysis of gene expression in LL2 tumors affected by taxifolin in comparison to DMSO-treated LL2 tumors using KEGG gene set. Analysis was performed using ClusterProfiler. B. The human homologous genes of the above LL2 tumors were analyzed by GSEA using MSigDB C8 cell type signature gene sets.
[0044] FIG. 9. Prediction of resistance to ICB. Evaluation of TxflSig, TxflSig1, IIT (ITGAL+ITGAX+TMEM119) , ITGAL, and ITGAX (A-E) along with a set of published ICB biomarkers (F) in the set of ICB-treated cohorts organized by the TIDE platform (http: / / tide. dfci. harvard. edu / login / ) . Please note that, in each panel A-F, the cohorts from top to bottom correspond to the cohort labels from left to right in the bottom left corner, respectively.
[0045] FIG. 10. Stratification of OS in the indicated cancer cohorts treated with the indicated ICB therapies by TxflSig, TxflSig1, ITGAL, ITGAX, and IIT. Top panel: Kaplan-Meier survival curves for the indicated biomarkers; bottom panel: summary of mortality risk stratification by our biomarkers along with a set of well-studied ICB biomarkers.
[0046] FIG. 11. Negative association of taxifolin-upregulated genes with factors promoting immune evasion in NSCLC. A. Association of the indicated DEGs upregulated by taxifolin in LL2 tumors with T cell dysfunction value; analysis was performed using the TIDE platform. B., C. PRDX6, MAGOHB, NUCKS1, DCAF13, and TXN were analyzed as a panel (PMNDT) in the stratification of OS probability in the indicated cohort. Analysis was performed using the TIDE platform. D. E. Negative correlation of PRDX6, MAGOHB, NUCKS1, DCAF13, and TXN with the indicated immune checkpoints in LUAD and LUSC. Correlation (spearman) analysis was performed using the TISIDB platform. Please note that, in panels D-E, individual genes in each immune checkpoint group from left to right correspond to the gene labels from left to right in the bottom, respectively.
[0047] FIG. 12. Spearman correlations of ITGAL, ITGAX, and TMEM119 with the indicated immune checkpoints (n = 24) across 30 human cancer types. Spearman correlation analyses were performed using the TISIDB platform.
[0048] FIG. 13. Spearman correlations of the indicated genes with immune checkpoints. PRDX6, MAGOHB, NUCKS1, DCAF13, and TXN, whose mouse homologous genes were upregulated by taxifolin in LL2 tumors, were analyzed for spearman correlation with the indicated immune checkpoints (n = 24) across 30 human cancer types using the TISIDB platform. Both LUAD and LUSC cancer types are bordered by dotted lines. Please note the general negative correlations of these genes with the indicated immune checkpoints in LUAD and LUSC.
[0049] FIG. 14. Correlation of ITGAL, ITGAX, and TMEM119 with cancer-associated immune cells. Spearman correlations of ITGAL, ITGAX, and TMEM119 with the indicated immune cell types across n = 30 human cancer types. Correlations were determined using TISIDB.
[0050] FIG. 15. Association of taxifolin-upregulated genes with immune cell content in cancers. PRDX6, MAGOHB, NUCKS1, DCAF13, and TXN, whose mouse homologous genes were upregulated by taxifolin in LL2 tumors, were analyzed for spearman correlation with the indicated immune cell types across 30 human cancer types using the TISIDB platform. Both LUAD and LUSC cancer types are bordered by two dotted lines. Please note that, the general negative correlation of these genes with the indicated immune checkpoints in LUAD and LUSC.
[0051] FIG. 16. ITGAL protein expression in LUAD and LUSC. Two images each for IHC staining of ITGAL in LUAD and LUSC tissue microarray were downloaded from the Human Protein Atlas. T: tumor cells; TN: tumor necrosis.
[0052] FIG. 17. ITGAX protein expression in LUAD and LUSC. Two images each for IHC staining of ITGAX in LUAD and LUSC tissue microarray were downloaded from the Human Protein Atlas. TN: tumor necrosis.
[0053] FIG. 18. TMEM119 protein expression in LUAD and LUSC. Two images each for IHC staining of TMEM119 in LUAD and LUSC tissue microarray were downloaded from the Human Protein Atlas. T: tumor cells; TN: tumor necrosis. Two staining of TMEM119 in normal tissues are also included.
[0054] FIG. 19. Prediction of OS by IIT in LUSC. A. Stratification of mortality risk of LUSC using the TCGA PanCancer Atlas LUSC dataset. B. Univariate (UV) and multivariate (MV) Cox analysis of LUAD mortality risk using IIT and the indicated clinical features. Sex: men compared to women; Mstage: M1 versus M0;Nstage: 1 (N ≥ 1) versus N0; and Tstage: 1 (T3+T4) compared to 0 (T1+T2) . C. Stratification of mortality risk by IIT together with the above clinical features (IIT+Clinicalfeature) . D., E. Discrimination of OS by IIT+Clinicalfeature with ROC-AUC (receiver operating characteristic-area under the curve) and precision recall (PR) -AUC curves for LUSC.DESCRIPTION OF EMBODIMENTS
[0055] The disclosure will be further described in combination with specific embodiments. It should be emphasized that these embodiments are only for illustrative purposes and are not intended to limit the scope of the disclosure. In addition, any reagents, devices, materials, etc. used in the disclosure are commercially available without special designation.
[0056] Definition
[0057] The term “taxifolin” as used herein refers to taxifolin compound itself, a derivative thereof, a pharmaceutical salt thereof, or any combination thereof.
[0058] “Taxifolin-treatment” means a treatment with taxifolin itself, or its derivative, or its pharmaceutically acceptable salts, or any combination thereof. In other words, any form of taxifolin may be used for treating BC as long as it can provide the same anti-oxidative effect as the taxifolin itself. The derivative or pharmaceutically acceptable salts of taxifolin may be those that have the effects of relieving inflammation, resisting oxidation, promoting cell programmed death, etc.
[0059] “Subject” used in the disclosure refers to an animal as an experiment, treatment, or observation object, preferably mammals, more preferably human.
[0060] The term “about” used in the disclosure refers to a range of value ±10%of the specified value. For example, the phrase “about 5 mg / kg” means a range of 4.5 to 5.5 mg / kg.
[0061] In this disclosure, a systemic investigation of taxifolin-derived anti-NSCLC actions was carried out. In the analysis of the mechanisms underlying taxifolin’s inhibition of murine LL2 cell-produced tumors which models human NSCLC, the inventors detected down-regulation of Itgal, Itgax, and Tmem119 gene expression among more than 500 differentially expressed genes (DEGs) resulted from taxifolin treatment. In both TCGA LUAD and LUSC cohorts, ITGAL, ITGAX, and TMEM119 expressions were robustly correlated with tumor-associated myeloid-derived suppressor cells (MDSCs) , regulatory T cells (Tregs) , and macrophages along with the expression of multiple immune checkpoints; these correlations were also detected in a panel of human cancers. ITGAL, ITGAX, the combination of ITGAL-ITGAX-TMEM119 (IIT) , and two multigene panels (taxifolin signature / TxflSig and TxflSig1) all effectively predicted the response of NSCLC to anti-PD1-based ICB treatment, which outperformed CD274 (PD-L1) -based prediction. Collectively, this research advances the current understanding of immune escape in NSCLC and may shed light on improving the management of NSCLC patients for ICB therapy.
[0062] Materials and methods
[0063] Data sources
[0064] LUAD and LUSC TCGA datasets organized by cBioPortal and the Human Protein Atlas database were used.
[0065] Programs and Websites
[0066] The tools utilized included UALCAN, Metascape, and TISIDB. The R dplyr, survival, Maxstat, cutpointr, and other packages were also used.
[0067] Signature score assignment for individual tumors
[0068] The coefficient (coef) of multigene panel’s component genes in predicting overall survival probability of patients with LC was performed with multivariate Cox regression (the R Survival package) . Risk scores for individual tumors were calculated as: Sum (coef1 x Gene1exp + coef2 x Gene2exp + ……+ coefn x Genenexp) , where coef1 …coefn were the coefs of individual genes and Gene1exp ……Genenexp were individual gene expression.
[0069] Ethics statement
[0070] Animal experiments were performed according to the ethical policies and protocols approved by McMaster University Animal Research Ethics Board (20-03-12, an AUP number under which animal experimental protocols were approved. ) .
[0071] All the animal work protocols performed were approved by McMaster University Animal Research Ethics Board (20-03-12) . TCGA datasets utilized in this research have been approved for research (http: / / cancergenome. nih. gov / ) .
[0072] Generation of LL2 tumors and taxifolin treatment
[0073] Mouse LL2 LC cells were purchased from ATCC (American Type Culture Collection; ATCC CRL-1642) and cultured in DMEM medium supplemented with fetal bovine serum (FBS, 10%) . Mycoplasma contamination was routinely monitored by mycoplasma PCR detection kit (Abcam, ab289834) . Tumors were produced by subcutaneous (s. c. ) implementation of 104 LL2 cells resuspended in 50%Matrigel (Corning 356234) into 6-8 weeks old C57BL / 6 mice (Jackson 000664) . Taxifolin was dissolved in 100 μl PBS with 10%DMSO and administered intraperitoneally (i.p. ) into mice on Day 3 post tumor implantation followed by injections every 3 or 4 days at a dose of 50 mg / kg. Tumor volume was determined following published conditions (Yan J, Ojo D, Kapoor A, Lin X, Pinthus JH, Aziz T, et al. Neural Cell Adhesion Protein CNTN1 Promotes the Metastatic Progression of Prostate Cancer. Cancer research. 2016; 76 (6) : 1603-14) .
[0074] Taxifolin was provided by Jilin Jianwei Songkou Biotechnology Co., Ltd. with a purity > 90%. Taxifolin was freshly dissolved in DMSO (dimethyl sulfoxide) at 50 mg / 10 μl and diluted in PBS prior to animal application. DMSO diluted in PBS was used as the negative control.
[0075] In experiments, the reagents or materials used may be those commonly and commercially available in the art, unless otherwise specified.
[0076] RNA sequencing analysis
[0077] RNA sequencing analysis was performed following our established conditions (Jiang Y, Lin X, Kapoor A, He L, Wei F, Gu Y, et al. FAM84B promotes prostate tumorigenesis through a network alteration. Therapeutic advances in medical oncology. 2019; 11: 1758835919846372) . RNA was extracted from LL2 tumors treated with either DMSO or taxifolin (n=3 per group) with a miRNeasy Mini Kit (Qiagen, No. 217004) and enriched for poly (A) mRNA using Poly (A) mRNA Magnetic Isolation Modules. Unique dual indexes were used for library preparation, followed by sequencing at McMaster Genomics Facility using a pair-end, 2x 50 bp configuration on the Illumina NextSeq 2000 P3 flow cell, with 10M clusters aimed per sample. RNA-seq reads were processed and analyzed using Galaxy (https: / / usegalaxy. org / ) . Low quality reads and adaptor sequences were removed. Alignment to mouse genomic sequence (mm10) was carried out using HISAT2; read counts were then performed with the “Featurecounts” function. Differential gene expression was determined using DESeq2. KEGG analysis and GSEA (Gene Set Enrichment Analysis) were performed using Galaxy; the FGSEA (fast preranked GSEA) was used for GSEA analysis. Enrichment analyses were carried out using Metascape (https: / / metascape. org / gp / index. html# / main / step1) and ClusterProfiler.
[0078] Statistical analysis
[0079] Kaplan-Meier curves and logrank test were conducted by R Survival package and GraphPad Prism 7. Cox regressions were analyzed using R survival package. ROC (receiver-operating characteristic) curves were generated with the R PRROC package. Other statistical analyses including Mann Whitney test, Chi-Square test and one-way ANOVA were performed by GraphPad Prism 7 and SPSS 26. Data were presented as mean ± standard deviation (SD) . A value of p < 0.05 was considered statistically significant.
[0080] Results
[0081] Taxifolin inhibits lung cancer growth with a network action
[0082] Taxifolin’s anti-tumor actions are in accordance with its general health-promoting benefits. Here, the inventors investigated taxifolin’s impact on LC using likely the only syngeneic mouse NSCLC model available: Lewis lung carcinoma, which allows a comprehensive analysis under a fully immunocompetent in vivo environment. The inventors have previously optimized experimental conditions on taxifolin-derived inhibition of 4T-1 breast cancer growth in a syngeneic tumor model; intraperitoneal (i.p. ) injection of taxifolin at 50 mg / kg twice per week, which had no impact on weight gain in mice, and displayed a clear inhibition of tumor growth. With the optimized conditions, taxifolin significantly delayed LL2 tumor growth in comparison to DMSO treatment (FIG. 1, panels A, B) .
[0083] To investigate the mechanisms underlying taxifolin-mediated inhibition of LL2 tumors, the inventors profiled gene expression in tumors treated with taxifolin or DMSO using RNA-seq. In comparison to DMSO, taxifolin affected gene expression in LL2 tumors (FIG. 1, panel C) . Gene Set Enrichment Analysis (GSEA) using the gene ontology (GO) gene sets revealed that in LL2 tumors, taxifolin treatment resulted in: 1) positive enrichment of gene sets regulating extracellular matrix and immunological processes, and 2) negative enrichment of pathways regulating cell proliferation, including small G proteins (Rho and Ras) , cell’s proliferation machinery (microtubule nucleation, growth cone, centrosome localization, and spindle pole) , and key signaling events (membrane receptor complex, TORC1 signaling, and MAP kinase activity) (FIG. 1, panels D, E) . Similar enrichments were also obtained using the KEGG gene sets (FIG. 8, A) . To analyze the relevance of these enrichments to human LC, the inventors further converted the mouse genes to the human homologous genes and performed GSEA with C8 cell type signature gene set (https: / / www. gsea-msigdb. org / gsea / msigdb / ) ; a set of enrichment relevant to lung cells was noted (FIG. 8B) . The above analyses support taxifolin-derived network action in inhibiting LL2 tumor growth, which is likely relevant to human LC pathogenesis.
[0084] Further, the inventors identified taxifolin-induced differentially expressed genes (DEGs) in LL2 tumors (Table 1) , which were defined as q < 0.05 and fold change ≥ |1.5| compared to gene expression in DMSO-treated tumors. The positive DEGs (i.e., those DEGs up-regulated by taxifolin) were enriched in extracellular matrix-and immune cell-related events (FIG. 1, panel F) ; enrichment by those down-regulated DEGs included the processes relevant to G-protein regulation and integrin signaling (FIG. 1, panel G) which is highly relevant to immune escape of LC detected in this study. Collectively, the above evidence supports taxifolin-derived suppression of LC pathogenesis through a network, including processes relevant to cell proliferation and immunity.
[0085] The immune component of taxifolin-induced DEGs in predicting NSCLC response to ICB therapy
[0086] The PD-1 / PD-L1 axis and CTLA4-based ICB therapies constitute the first-line treatment for NSCLC without targeted therapies. In view of the enrichments in processes relevant to immune regulations in LL2 tumors treated with taxifolin (FIG. 1, panels, D, F) , we analyzed the immune component affected by taxifolin. The murine DEGs (n = 578, Table 1) were converted to the corresponding human genes (n = 539, Table 2) , and then screened for their T (cytotoxic T lymphocyte / CTL) cell dysfunction values in 5 datasets (neuroblastoma, leukemia, breast cancer, endometrial cancer, and melanoma) using the Regulator Prioritization function in the TIDE platform. These values reflect individual factors’ involvement in CTL-mediated killing of tumor cells; for instance, positive and negative T cell dysfunction values indicate the inhibitory and facilitatory impact on CTL’s tumor cell killing activities respectively. Here, the 12 genes with positive T cell dysfunction values > 0.5 in all 5 datasets (FIG. 2, A, top panel) were focused; these genes were associated with overall survival (OS) probability in multiple cohorts treated with ICB (FIG. 2, A, bottom panel) . These 12 genes formed a multi-gene panel TxflSig (taxifolin signature) which predicted response to ICB therapy in multiple cohorts at AUC (area under the curve) value > 0.5; with 5 cohorts (including a NSCLC cohort) showing AUC ≥ 0.7 (FIG. 9A) . The predictions were comparable to some well-established ICB biomarkers (FIG. 9F) . In a NSCLC, melanoma, and glioblastoma cohort, TxflSig exhibited superiority to several effective ICB biomarkers in predicting response to ICB treatments, including TIDE, MSI. score (microsatellite instability) , CD274 (PD-L1) , CD8, and INFG (INFγ) (FIG. 2, panel B) .
[0087] Table 1. DEGs (taxifolin compared to DMSO) of mouse genes
[0088] Table 2. Human homologous genes of murine DEGs
[0089] The possession of positive T cell dysfunction value for all TxflSig component genes (FIG. 2, A, top panel) reveals their inhibition of CTL function, and potential contributions to immune evasion in cancer. In this regard, the murine counterparts of STRA6, TMEM119, ITGAX, MINK1, NBEAL2, GBP4, and ITGAL genes were down-regulated in taxifolin-treated LL2 tumors (Table 1) , which is consistent with their potential roles in inhibiting CTL functions. This suggests a potential biomarker value of these genes in predicting the response of NSCLC to ICB therapy. This panel was named as TxflSig1, which included STRA6, TMEM119, ITGAX, MINK1, NBEAL2, GBP4, and ITGAL. In comparison to TxflSig, TxflSig1 displays improved performance as an ICB biomarker (comparing FIG. 9B to FIG. 9A) . Importantly, TxflSig1 predicted NSCLC response to anti-PD1 therapy at AUC of 0.8, which was the best among all well-established ICB biomarkers, including CD274, IFNG, and Merck18 (T-cell-inflamed signature) (FIG. 2, panel B) .
[0090] Among the 7 component genes of TxflSig1, recently several interesting observations of GBP4 were further made, including its induction by a gain-of-function PCSK9 mutant in melanoma; its expression being positively association with T cell dysfunction, and its biomarker value in predicting response to ICB therapy. Additionally, both ITGAL and ITGAX effectively predict NSCLC response to PD1-based ICB treatment as individual genes; with a robustness matching or outperforming other established ICB biomarkers-derived predictions (FIG. 2, C) . While TMEM119 displayed modest ICB biomarker potential (data not shown) , the combination of it with ITGAL and ITGAX formed the IIT (ITGAL+ITGAX+TMEM119) panel with improved ICB biomarker potential in the “Ruppin2021_PD1_NSCLC” cohort organized by TIDE (FIG. 2C) . Additionally, ITGAL, ITGAX, and IIT possessed effective ICB biomarker potentials towards glioblastoma, melanoma, gastric cancer, and others in analogous effectiveness compared to those of well-established ICB biomarkers (FIG. 9C-F) .
[0091] To further support the above analyses, TxflSig, TxflSig1, ITGAL, ITGAX, and IIT all predicted OS probabilities in multiple cohorts treated with ICB, including melanoma and clear cell renal cell carcinoma (ccRCC) (FIG. 2, panels D-H; FIG. 10) .
[0092] In addition to taxifolin-downregulated genes discussed above, 5 genes (Prdx6, Magohb, Nucks1, Dcaf13, and Txn1) were up-regulated by taxifolin in LL2 tumors (Table 1) ; their human homologous genes, PRDX6, MAGOHB, NUCKS1, DCAF13, and TXN, possessed negative T cell dysfunction values < -1 in all 5 TIDE datasets (FIG. 11A) , indicating their actions in facilitating CTL function. The magnitude of this facilitation was more prominent than SOX10, a top candidate identified to promote CTL-derived killing of cancer cells. PRDX6 (peroxiredoxin 6) and TXN (thioredoxin) are known for their antioxidant activities and TXN enhances NK cells-derived anti-cancer immunity in tumor microenvironment (TME) , suggesting a potential for their inductions to contribute to taxifolin’s antioxidant actions. Although PRDX6, MAGOHB, NUCKS1, DCAF13, and TXN gene as a panel may display weak prediction of ICB response (data not shown) , the panel robustly stratified overall survival in patients with melanoma treated with anti-PD1 following progression on anti-CTLA4 therapy (FIG. 11, panels B, C) . It is evident that taxifolin’s suppressive effects on NSCLC are attributable to at least in part via the sensitization of LC to immune reactions.
[0093] Robust correlation of ITGAL, ITGAX, and TMEM119 with immune checkpoints
[0094] Immune checkpoints play critical roles in cancer cell’s evasion of immune surveillance. Of note, using the TCGA Firehose Legacy cohorts within the cBioPortal platform, the inventors detected high-level correlations of ITGAL with TIGIT, CD96, and BTLA in LUAD (n = 517) and with TIGIT, CD96, and PDCD1 in LUSC (n = 501) (FIG. 3, panel A) . High levels of correlation were also observed between ITGAX and CSF1R, HAVCR2, or CTLA4 in both LUAD and LUSC (FIG. 3, panel A) . The inventors defined high-level correlation at Spearman correlation (rho) ≥ 0.5. With the setting of ITGAL, ITGAX, or TMEM119 displaying a high-level correlation with immune checkpoints, ITGAL and ITGAX exhibited high levels of correlation with n = 18 immune checkpoints in LUAD (FIG. 3, panel B) ; similarly, ITGAL, ITGAX, and TMEM119 correlated with n = 19 immune checkpoints in LUSC (FIG. 3, panel C) . The top correlations of ITGAL with TIGIT and CD96 in both LUAD and LUSC suggest the major immune checkpoints utilized by ITGAL in facilitating the immune escape (FIG. 3, panels B, C) . Similarly, ITGAX may enhance the immunosuppressive actions of HAVCR2 and CSF1R in LUAD and LUSC (FIG. 3, panels B, C) , while TMEM119 facilitates LUSC immune evasion via CSF1R (FIG. 3, panel C) . Nonetheless, this does not exclude the network actions of all individual immune checkpoints in ITGAL-, ITGAX-, and TMEM119-derived immune evasion in NSCLC. Furthermore, the high levels of correlation observed above were not limited to NSCLC but across 30 human cancer types including LUAD and LUSC (FIG. 12) . Collectively, the above evidence supports the role of taxifolin-downregulated ITGAL, ITGAX, and TMEM119 in enhancing NSCLC immune evasion.
[0095] Similarly, the mouse homologous genes of human PRDX6, MAGOHB, NUCKS1, DCAF13, and TXN were u-pregulated by taxifolin in LL2 LC tumors (Table 1) and facilitated CTL-derived toxicity towards cancer cells (FIG. 11A) . In this regard, PRDX6, MAGOHB, NUCKS1, DCAF13, and TXN displayed an overall negative correlation with multiple immune checkpoints in LUAD, LUSC (FIG. 11D, E) and other cancer types (FIG. 13) . These observations further support the impact of taxifolin-affected genes on modulating TME-associated immunity in part via their interactions with immune checkpoints.
[0096] A substantial correlation of ITGAL, ITGAX, and TMEM119 with LC-associated MDSC, Treg, and macrophages
[0097] Infiltration of myeloid-derived suppressor cells (MDSCs) , regulatory T cells (Treg) , and macrophages play critical roles in shaping immunosuppressive TME. Of note, ITGAL and ITGAX were dramatically correlated with the content of MDSC and Treg in both LUAD and LUSC (FIG. 4, panel A) . TMEM119 was robustly associated with MDSC and Treg in NSCLC (FIG. 4, panels B, C) . In addition, ITGAL, ITGAX, and TMEM119 were also strongly correlated with macrophages and other immune cell populations in LUAD and LUSC (FIG. 4, panels B, C) as well as across a panel of human cancer types (FIG. 14) . However, the strong association with a range of immune cells, including activated CD8 (Act CD8) and NK cells with demonstrated anti-tumor actions, indicates the dynamic nature of TME, and particularly the continuous actions between pro-and anti-tumor activities present in TME. In this regard, it is also found that different B cell populations exist in TME with pro-and anti-tumor activities (FIG. 4, panels B, C) . Alternatively, the infiltrated CD8+ T and NK cells might be dysfunctional or in an anergic state owing to the high-level correlations of ITGAL, ITGAX, and TMEM119 with immune checkpoints, including TIGIT, CD96, PVRIG, CTLA4, CD274, and others (FIG. 3) . TIGIT, CD96, and PVRIG are immune checkpoints for both NK and CD8+ T cells. Collectively, the above evidence supports the facilitative roles of ITGAL, ITGAX, and TMEM119 in shaping immunosuppressive TME for LUAD and LUSC.
[0098] The above inference is supported by the opposite correlations of PRDX6, MAGOHB, NUCKS1, DCAF13, and TXN genes, the human counterparts of murine genes upregulated in taxifolin-treated LL2 tumors (Table 1) , with NSCLC-associated immune cells. These genes were associated with negative T cell dysfunction value (FIG. 11A) , negatively correlated with the content of MSDC, Treg, macrophages in both LUAD and LUSC (FIG. 4, panels D, E) , and displayed a general negative association with MSDC, Treg, and macrophages across a set of human cancer types (FIG. 15) . Taken together, it was demonstrated that there is a robust association of ITGAL, ITGAX, and TMEM119 with the major immunosuppressive immune cell types (MDSC, Treg, and macrophages) in LUAD and LUSC, suggesting a contribution of their reductions to taxifolin-derived inhibition of NSCLC pathogenesis.
[0099] Expression status of ITGAL, ITGAX, and TMEM119 in LC
[0100] PRDX6, MAGOHB, NUCKS1, DCAF13, and TXN displayed opposite trends on their potential facilitation of CTL function as well as correlations with immune checkpoints and TIL (tumor-infiltrating lymphocytes) compared to ITGAL, ITGAX, and TMEM119 in NSCLC. Nonetheless, their negative correlations were modest compared to the positive correlations displayed by ITGAL, ITGAX, and TMEM119 (comparing FIG. 3, panels B, C to FIG. 11D, E and comparing FIG. 4, panels B, C to FIG. 4, panels D, E) . Additionally, ITGAL, ITGAX, and TMEM119 effectively predicted NSCLC response to ICB therapy both individually and as a panel (FIG. 2, panel C; FIG. 9C-E) .
[0101] By using the UALCAN platform (http: / / ualcan. path. uab. edu / index. html) , the inventors observed a general reduction of ITGAL, ITGAX, and TMEM119 in LUAD at both the mRNA and protein expression levels (FIG. 5A-C, H-J) as well as their downregulation in LUSC at the mRNA level (FIG. 5K-M) . Additionally, further downregulations of ITGAL, ITGAX, and TMEM119 in stages 3 and 4 compared to stage 1 LUAD were observed (FIG. 5D-E) ; and reductions of ITGAX and TMEM119 in stage 4 compared to stage 2 LUAD were also detected (FIG. 5E, F) . LUAD tumors with lymph node metastasis (N2) displayed lower TMEM119 expression compared LUAD without the metastasis (FIG. 5G) . For LUSC, further downregulations of ITGAL, ITGAX, and TMEM119 occurred in tumors with TP53 mutations compared to those without TP53 mutations (FIG. 5N-P) . Collectively, evidence indicates downregulations of ITGAL, ITGAX, and TMEM119 following NSCLC tumorigenesis and progression.
[0102] To gain further insights on the involvement of ITGAL, ITGAX, and TMEM119 in NSCLC, the inventors further analyzed their protein expression. By taking advantage of the protein expression data within the Human Protein Atlas, the inventors observed a general presence of ITGAL and ITGAX in the stromal compartment but not in tumor cells in both LUAD and LUSC (FIG. 6, panels A, B; FIG. 16; FIG. 17) . In some LUSC, ITGAL expression was present in lymphoid aggregates and tumor necrosis (FIG. 6, panel A; FIG. 16) . Similarly, ITGAX was also detected in immune cells and tumor necrosis in LUAD and LUSC (FIG. 6, panel B; FIG. 17) . In both LUAD and LUSC, the nuclear expression of TMEM119 in tumor cells is apparent (FIG. 6, panel C; FIG. 18) ; its presence in stromal and tumor necrosis could also be detected (FIG. 6, panel C; FIG. 18) . In normal lung tissues, TMEM119 is expressed in both the nucleus and cytoplasm (FIG. 18) . Tumor necrosis promotes metastasis and is associated with poor prognosis; the presence of ITGAL, ITGAX, and TMEM119 in tumor necrosis suggests their roles in facilitating NSCLC progression.
[0103] The detection of ITGAL and ITGAX in immune cells was not surprising, given these genes encode for the integrin α L subunit (αL or CD11a) and αX (CD11c) subunit respectively. Together with the integrin β2 (CD18) subunit, the αLβ2 integrin or lymphocyte function-associated antigen-1 (LFA-1) plays essential roles in T cell migration and activation via interaction with antigen-presenting cells (APCs) ; αXβ2 is crucial in myeloid cells (neutrophils, monocytes, and dendritic cells) motility and pathogen phagocytosis. TMEM119 is a recently identified marker for microglia, the resident macrophages in the central nervous system (CNS) .
[0104] IIT-mediated stratification of NSCLC OS probabilities
[0105] To further define the connection of ITGAL, ITGAX, and TMEM119 to NSCLC, the inventors studied their multigene panel IIT (ITGAL-ITGAX-TMEM119) in predicting the mortality risk of NSCLC. This effort was supported by the formation of the IIT panel in predicting response of NSCLC to ICB treatment (FIG. 2C) ; the potential of ITGAL, ITGAX, and TMEM119 was further supported by their significant, albert imperfect correlations in both LUAD and LUSC (Table 3) . Using the TCGA PanCancer Atlas LUAD dataset, the IIT risk score for individual tumors was calculated by using the formula: ∑ (coefi x Geneiexp) n (coefi: Cox coefficient of genei, Geneiexp: expression of Genei, n = 3) . Coefs were obtained using the multivariate Cox model. Patients in the high-score group were associated with poor mortality (FIG. 7A) . Similarly, IIT also stratified the mortality risk of patients with LUSC (FIG. 19A) . After adjusting for a set of clinical features including age, sex, M stage, N stage, and T stage, IIT remains a risk factor for fatality in LUAD but not LUSC (FIG. 7B; FIG. 19B) . Nonetheless, the inclusion of those clinical features (IIT+Clinicalfeature) significantly improved IIT’s biomarker potential in the stratification of LUAD-and LUSC-associated fatality risk (FIG. 7C; FIG. 19C) ; the discrimination of the mortality risk by IIT+Clinicalfeature was at ROC-AUC (receiver operating characteristic –area under the curve) values of 0.7 for LUAD (FIG. 7, panel D) and 0.61 for LUSC (FIG. 19D) , and PR (precision recall) -AUC values of 0.56 for LUAD (FIG. 7, panel E) and 0.53 for LUSC (FIG. 19E) .
[0106] Table 3. Spearman correlations among ITGAL, ITGAX, and TMEM119 in LUAD and LUSC
[0107] Spearman correlation (rho) was determined using the TCGA Firehole Legacy LUAD (n = 510) and LUSC (n = 501) datasets; i: LUAD; ii: LUSC
[0108] Further, IIT+Clinicalfeature biomarker potential in LUAD was examined by estimating cutoff points using the empirical, kernel, and normal methods with 1000 bootstraps using the R cutpointr package. The median ROC-AUC in both the in-bag and out-of-bag 1000 bootstrapping samples was 0.70 and 0.69 respectively for the empirical method and 0.7 for the kernel and normal method. With a range of cutoff points estimated by maxstat, empirical, kernel, and normal method, effective stratification of LUAD mortality was achieved; however, sensitivity and specificity associated with these cutoff points could be improved (FIG. 7, panel F) . Nonetheless, the biomarker potential of IIT in the estimation of OS probability of LUAD and LUSC supports the contributions of ITGAL, ITGAX, and TMEM119 in LUAD and LUSC pathogenesis.
[0109] In sum, the above suggests taxifolin as a potential addition to ICB treatment. Taxifolin significantly delayed the growth of LL2 tumors, a syngeneic model of human NSCLC. One of the network components contributing to taxifolin-derived inhibition of LL2 tumors affected tumor-associated immunity. For instance, the human homologous genes for the murine genes upregulated by taxifolin in LL2 tumors included Prdx6, Magohb, Nucks1, Dcaf13, and Txn1 act to facilitated CTL-mediated killing of tumor cells, as shown by their negative T cell dysfunction values. On the other hand, Itgal, Itgax, and Tmem119 in LL2 tumors were downregulated by taxifolin; their human counterparts (ITGAL, ITGAX, and TMEM119) displayed positive T cell dysfunction values, suggesting their negative impact towards CTL-derived cytotoxicity on tumor cells. These observations are further supported by the negative correlations of PRDX6, MAGOHB, NUCKS1, DCAF13, and TXN with immune checkpoints and MDSC, Treg, and macrophages in comparison to the robust positive correlations of ITGAL, ITGAX, and TMEM119 with immune checkpoints and MDSC, Treg, and macrophages.
[0110] The robust and positive correlations of ITGAL, ITGAX, and TMEM119 with numerous immune checkpoints, including TIGIT, CD96, PDCD1 (encoding PD-1) , CTLA4, LAG3, CD274 (PD-L1) , VISTA, ICOS, BTLA, and others, as well as a set of immune cells including MDSC, Treg, and macrophages in NSCLC and across human cancer types strongly suggest the general immunosuppressive actions of ITGAL, ITGAX, and TMEM119 in NSCLC and human cancers. This is a novel property for all 3 genes. LFA-1 (αLβ2) ’s adhesion function achieved via binding to ICAM-1 (intercellular adhesion molecule 1) is essential for T cell migration and activation through interaction with APCs. In vitro, LFA-1 contributed to the generation of CD4+ T cells with Treg properties. LFA-1 was detected on MDSC cell surface; evidence also suggests a role of LFA-1 in MDSC generation. In this regard, it can be speculated that in TME, LFA-1 may be tailored to the generation of Treg and MDSC and thus facilitates immune evasion in NSCLC.
[0111] In addition, ITGAL strongly correlates with TIGIT and CD96 at spearman rho ≥ 0.8 in both LUAD and LUSC. Both TIGIT and CD96 inhibit NK and T cell function via binding CD226, indicating a possibility that ITGAL may suppress NK and CD8+ T cell’s killing activities of tumor cells.
[0112] Based on the above, ITGAL, ITGAX, and the panel of these three genes (IIT) predict the response of NSCLC to anti-PD1 therapy more efficiently than the panel of well-established ICB biomarkers, including PD-L1 (CD274) , INFγ, CD8, and Merck18. This level of robustness is also reflected in the performance of TxflSig and TxflSig1. In light of the unmet need for better ICB biomarkers in NSCLC, the novel ICB biomarkers revealed herein may improve the stratification of NSCLC patients that can benefit from ICB treatments. Furthermore, taxifolin inhibits NSCLC via a network action, including down-regulation of TME-associated immune evasion capacity. This opens the possibility of including taxifolin in the current regimen of ICB therapy in NSCLC. This possibility can be readily tested in clinical trials, owing to taxifolin’s status as a nutritional supplement. Several novel biomarkers in predicting NSCLC response to ICB therapy were identified, including ITGAL, ITGAX, IIT, TxflSig, and TxflSig1. Importantly, they demonstrated higher robustness compared to not only the current ICB biomarker (PD-L1) used in NSCLC patients, but also those of well-studied pan-cancer ICB biomarkers. Thus, these panel’s ICB biomarker potential, particularly in LC, are worthy of further examination. NSCLC as well as other human cancers may utilize ITGAL, ITGAX, and TMEM119 to shape TME into an immunosuppressive TME. This research possesses clinical and basic research potential in improving the management of patients with NSCLC.
[0113] Finally, it should be noted that the foregoing embodiments are merely intended for describing the technical solutions of the present disclosure other than limiting the present disclosure. Although the present disclosure is described in detail with reference to the foregoing embodiments, persons of ordinary skill in the art should understand that they may still make modifications to the technical solutions described in the foregoing embodiments or make equivalent substitutions to some technical features thereof, without departing from the spirit and scope of the technical solutions of embodiments of the present disclosure.
Claims
1.A biomarker for assessing lung cancer (LC) response to immune checkpoint blockage (ICB) therapy, wherein the biomarker is selected from at least one of ITGAL, ITGAX, TMEM119, STRA6, MINK1, NBEAL2, GBP4, GFRA4, SLIT3, ARHGDIB, ASCL2, ACP5, PRDX6, MAGOHB, NUCKS1, DCAF13, and TXN, or any combination thereof.2.The biomarker according to claim 1, wherein the biomarker is a combination of ITGAL, ITGAX, and TMEM119; a combination of ITGAL, ITGAX, TMEM119, STRA6, MINK1, NBEAL2, and GBP4; or a combination of ITGAL, ITGAX, TMEM119, STRA6, MINK1, NBEAL2, GBP4, GFRA4, SLIT3, ARHGDIB, ASCL2, and ACP5; or a combination of PRDX6, MAGOHB, NUCKS1, DCAF13, and TXN.3.The biomarker according to claim 1 or 2, wherein the lung cancer (LC) is small-cell lung cancer (SCLC) or non-small-cell lung cancer (NSCLC) , optionally, the NSCLC is lung adenocarcinoma (LUAD) , lung squamous cell carcinoma (LUSC) , or large cell carcinoma.4.The biomarker according to any one of claims 1-3, wherein the biomarkers ITGAL, ITGAX, TMEM119, STRA6, MINK1, NBEAL2, and GBP4 each are down-regulated in a lung cancer (LC) subject after taxifolin-treatment.5.The biomarker according to any one of claims 1-3, wherein the biomarkers PRDX6, MAGOHB, NUCKS1, DCAF13, and TXN each are up-regulated in a lung cancer (LC) subject after taxifolin treatment.6.The biomarker according to any one of claims 4-5, wherein the taxifolin is administered to the lung cancer (LC) subject at a therapeutically effective amount of 5-100 mg / kg body weight;optionally, the taxifolin is administered to the lung cancer (LC) subject at the therapeutically effective amount of 10-90, 20-80, 30-60 or 40-70 mg / kg body weight.7.A kit for assessing a response of a lung cancer (LC) subject to taxifolin-treatment, comprising a detecting agent for detecting expression of the biomarker of any one of claims 1-6 in the lung cancer (LC) subject, and an instruction for use.8.A method for assessing a response of a lung cancer (LC) subject to taxifolin-treatment, comprising determining an expression level of at least one of the biomarker according to any one of claims 1-6 in a biological sample obtained from the lung cancer (LC) subject after taxifolin-treatment, and comparing the expression level with an expression level of the at least one of the biomarker in a biological sample obtained from the lung cancer (LC) before taxifolin-treatment.9.The method according to claim 8, wherein the method further comprises: determining the taxifolin-treatment is effective when the lung cancer (LC) subject has a positive response to the taxifolin-treatment;optionally, the method further comprises: determining the taxifolin-treatment is effective when one or more of biomarkers ITGAL, ITGAX, TMEM119, STRA6, MINK1, NBEAL2, and GBP4 is down-regulated; or one or more of biomarkers PRDX6, MAGOHB, NUCKS1, DCAF13, and TXN is up-regulated.10.A method for preventing, alleviating or treating lung cancer (LC) , in particular, non-small-cell lung cancer (NSCLC) in a subject, comprising administering taxifolin or derivative thereof, or a pharmaceutical acceptable salt thereof to a subject that is underwent an immune checkpoint blockage (ICB) , and determining a level of a biomarker in tumor cell from the subject, wherein the biomarker is any one of the biomarker according to any one of claims 1-5, or any combination thereof.
Citation Information
Patent Citations
Methods and compositions for prognosis and treatment of cancers
CN107208138A
Gene signature for immune therapies in cancer
CN108138236A
Gene sets and scoring model for evaluating tumor microenvironment, and application of gene sets
CN112133365A
Molecular gene signatures and methods of using same
CN112771177A
